Novartis drops elinogrel outright
This article was originally published in Scrip
Novartis has dealt another blow to its late-stage antiplatelet candidate elinogrel under cover of a major restructuring announcement. While announcing swingeing cuts to its US primary care sales force (scripintelligence.com, 13 January 2012), Novartis has also dropped elinogrel, once tipped as a blockbuster but quietly refocused in the pipeline last year.
You may also be interested in...
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.
Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.
INFOGRAPHIC: A snapshot of the compensation packages granted to the chiefs of the world’s biggest pharma companies, along with key performance stats for the businesses they lead.